GOTHENBURG, Sweden, September 20, 2011 /PRNewswire/ --
Cellectricon appoints David Burns as the company's Chief Executive Officer. David brings a solid and highly impressive international Life Science executive track record to Cellectricon vital for the company's continued market expansion in bringing state-of-the-art screening solutions for drug discovery and cell-based research.
David Burns has extensive experience of the life sciences industry and has held executive management positions at Renishaw Diagnostics Ltd., Cyntellect Inc., GE Healthcare, Imaging Research Inc, BioSignal Packard Inc., and Pharmacia / LKB Ltd. Significantly; Mr. Burns has previously developed several companies through to outstanding commercial success.
Cellectricon's Chairman Axel Broms said: "The board is delighted with the appointment of David as the new CEO. We are looking forward to working with him in formulating and broadening the product offering using the Company's strong IP and technology position. David's experience in both research instruments and service businesses complements Cellectricon's strategic aim to deliver more value to its customers by offering assay development services based on Cellectricons in-house technology expertise in addition to instrument sales."
David Burns added: "Cellectricon is a remarkable company with strong customer validation and well-earned reputation for providing groundbreaking products and services to the pharmaceutical and biotechnology industries. I will focus on providing strategic, operational, and customer relationship continuity. This will ensure that our customers can depend on Cellectricon to accelerate their drug discovery and biological research by continued development of new products and services, as well as an outstanding customer support. "
Cellectricon AB, Sweden, is a leading life sciences solutions provider of advanced screening products and services to accelerate drug discovery and cell-based assay research. The company is a total solutions provider of customized instruments to discovery services solving critical bottlenecks in drug discovery & cell based research. The proprietary technologies include industry leading platforms for high resolution ion-channel screening, and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess®HT System enables high throughput transfection for genomic screening and the new Dynaflow®HT System greatly advances ion channel drug discovery.